Sporadic Inclusion Body Myositis — Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Citation(s)
A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis